Epiduo Forte

Quick links to important sections

Epiduo Forte

Selected form

Treatment option: Zits, Acne Vulgaris

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Epiduo Forte

Property Description
Active Ingredients Adapalene, Benzoyl Peroxide
Form Opaque Topical Gel
Pharmacological Class Topical Acne Agent (Retinoid/Antiseptic Combination)
Common Use Management of Acne Vulgaris
Origin Synthetic Retinoid Derivative (Adapalene), Oxidizing Agent (Benzoyl Peroxide)

What Type of Medicine is Epiduo Forte?

Epiduo Forte is a prescription-only drug manufactured by Galderma and supplied as a white to very pale yellow, opaque topical gel intended for cutaneous use. It is formally classified as a Fixed-Dose Combination (FDC) product within the high-level Topical Acne Agents pharmacological class. This medicinal product is a distinct, higher-strength version of the original Epiduo formulation. Fixed-dose combination products are designed to simplify complex regimens and are associated with improved patient adherence in chronic conditions.

Dual Composition: Adapalene and Benzoyl Peroxide

The medication contains two primary active ingredients: Adapalene (0.3%) and Benzoyl Peroxide (2.5%). Adapalene is defined as a synthetic third-generation retinoid derivative, an advancement over earlier retinoids that is recognized for its targeted receptor activity and stability. Benzoyl Peroxide is an established oxidizing agent known for its antimicrobial properties. This pairing functionally categorizes the medicine as a Retinoid/Antiseptic combination. Combining agents like retinoids and antimicrobials is a treatment strategy for acne, intended to provide greater efficacy than monotherapies.

General Purpose and High-Level Action

The general purpose of Epiduo Forte is to provide comprehensive foundational support for managing Acne Vulgaris in adults and pediatric patients 12 years of age and older. The combined formulation achieves this by performing core, complementary actions that address the primary pathological factors of acne. The Adapalene component supports Skin Cell Normalization to help regulate the growth and shedding of follicular cells. Concurrently, the Benzoyl Peroxide component provides Bacterial Reduction by decreasing the population of P. acnes bacteria. This synergistic action is intended to interrupt the cycle of acne development, a common approach in dermatology for patients with a mix of non-inflammatory and inflammatory lesions.

What side effects are possible with Epiduo Forte?

Possible Side Effects and Safety Information

The official regulatory safety profile for Epiduo Forte gel is primarily characterized by local application site reactions which are classified as the most frequently occurring adverse events. These reactions are typically categorized as Very Common or Common based on clinical trial incidence data.

Documented Adverse Reactions and Frequencies

Classification Representative Adverse Reaction
Very Common Erythema (redness), Scaling, Dryness, Stinging/burning sensation
Common Skin irritation, Eczema, Atopic dermatitis

These local effects are most likely to occur during the first four weeks of treatment and are generally documented to lessen with continued use of the medication. Reactions are primarily confined to the Skin and subcutaneous tissue disorders system-organ class.

Serious Adverse Reactions and Safety Constraints

The regulatory profile formally notes that rare, but clinically important, systemic reactions have been reported in post-marketing surveillance, including Anaphylaxis and Angioedema (severe immune system disorders). Additionally, reports of serious local injury, such as Application Site Burn, have been documented.

Usage is subject to several safety constraints. The medication is contraindicated in individuals with a known hypersensitivity to any of its components. Use is associated with increased susceptibility to UV light, requiring avoidance of sun exposure and tanning beds. Furthermore, it must not be applied to damaged skin, such as cuts, abrasions, or sunburned areas. For pregnancy, European regulatory documents state a contraindication for use.

Overdose and Emergency Response

The official overdose profile for Epiduo Forte addresses two primary exposure scenarios: excessive topical application and accidental oral ingestion. Excessive topical application, though not leading to acute systemic overdose, may result in documented local cutaneous manifestations, including marked redness (erythema), peeling (exfoliation), and significant site discomfort (stinging or burning). The regulator-mandated action for this over-application is to discontinue use until the affected skin areas have fully recovered.

Accidental oral ingestion requires immediate medical attention as the drug is for external use only. Systemic exposure carries the potential for adverse effects similar to those associated with excessive oral intake of Vitamin A due to the retinoid component. For ingestion, immediate medical attention must be sought, and the patient must immediately telephone a doctor or a Poisons Information centre for guidance.

Management involves general supportive measures and appropriate symptomatic measures; activated charcoal may be administered to reduce drug absorption. Furthermore, pregnancy testing is a required procedural step for women of childbearing potential following ingestion due to the documented risk of teratogenesis. Severe systemic reactions, such as anaphylaxis or angioedema, also necessitate immediate contact with emergency services. No specific antidote is described in the official regulatory information.

Therapeutic Uses of Epiduo Forte

What Epiduo Forte Treats: Main Uses and Benefits

Epiduo Forte gel is indicated for the topical management of Acne Vulgaris in adults and pediatric patients 12 years of age and older. This combination is commonly applied to address symptom clusters that may become intense or disruptive, specifically addressing symptomatic clusters related to inflammatory and non-inflammatory manifestations. This combination supports symptomatic relief across the affected areas, which often include the face, chest, and back.


This medication is generally used in conditions characterized by periods of moderate to severe symptoms, especially when the condition involves numerous inflammatory manifestations or is often used during phases when symptoms become more noticeable or when previous symptomatic assistance has been required. The higher strength formulation may assist in easing the overall impact of difficult manifestations and supports patients coping more steadily with severe, recurring episodes. Support for continued use is provided against the development of new acne lesions, which assists with managing recurrence. The medication is aligned with therapeutic domains involving noticeable symptom expression, particularly in mixed lesion types. Maintaining control over new lesion formation supports improvements in skin appearance during symptomatic periods and may assist with reducing the likelihood of developing lasting acne scars.

Quick Fact: Supportive Management for Acne Vulgaris Symptoms
Symptom Domains Addressed: Mixed inflammatory and non-inflammatory lesions.
Typical Context: Conditions involving episodic or fluctuating manifestations, often moderate to severe.
Core Benefit: Provides support that helps ease the overall symptom burden and assists with maintaining functional stability.

Eligibility and Restrictions for Use

Who Can and Cannot Use Epiduo Forte? — Official Regulatory Information

This section summarizes the official population eligibility and non-eligibility rules for Epiduo Forte, as defined by governmental regulatory documents.

Eligibility Category Status as per Regulatory Label
Populations Allowed Adults and pediatric patients 12 years of age and older
Populations Contraindicated Patients with a known history of hypersensitivity to any component
Pregnancy Contraindicated in women who are pregnant or planning a pregnancy

Age and Physiological Restrictions

  • Pediatric Restriction: Safety and effectiveness have not been established in children under the age of 12.
  • Geriatric Use: Use is not established in patients 65 years and older, as regulatory studies did not include sufficient data for this group.
  • Lactation Status: Caution is advised; application to the chest, nipple, and areola is advised against to prevent direct infant exposure.

Condition-Specific Limitations

  • The medication must not be applied to skin areas affected by cuts, abrasions, eczematous conditions, or sunburn.
  • Use in patients with hepatic or renal impairment has not been officially established in the regulatory labeling.

Connection to the Overall Eligibility Profile:

Regulatory documents define eligibility through a strict minimum approved age and by absolute prohibitions against use in patients with hypersensitivity to any ingredient and during pregnancy. The official label also mandates that the medicine is not applied to compromised skin areas, which defines specific limitations for application.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The official interaction profile for Epiduo Forte is characterized by a high focus on localized pharmacodynamic effects and the absence of documented systemic interactions. Regulatory authorities classify the potential for systemic interaction with oral medicinal products as unlikely due to the minimal percutaneous penetration of adapalene and the rapid, local metabolism of benzoyl peroxide. No formal systemic drug-drug interaction studies have been conducted to assess exposure changes.

Interacting Product Category Regulatory Constraint
Other Topical Retinoids/Benzoyl Peroxide Products Concurrent Use Prohibited due to the risk of additive local irritancy.
Irritating Topical Agents Use with Caution due to the risk of cumulative irritancy effect.

The official prescribing information advises that the gel should not be used concurrently with other topical retinoids or other benzoyl peroxide products, as this co-administration may result in a severe cumulative irritancy effect. Caution is required when combining the gel with any concomitant topical acne therapy, as well as topical products known to possess abrasive, peeling, or strong drying properties. These include preparations containing high concentrations of alcohol, astringents, spices, or limes. The regulatory documents define the interaction structure based on this additive local reaction. Consequently, no mandatory timing or separation requirements are specified for systemic medications, and no population-specific interaction considerations are documented.

Mechanism of Action

How Epiduo Forte Works

The dual mechanism of this combination targets the mechanistic processes of follicular hyperkeratinization and C. acnes proliferation to influence the underlying cellular and microbial pathology. This integrated function involves both selective extbfRAR-gamma agonism and non-specific extbfoxidative action.

The retinoid component, extbfAdapalene, acts as a selective extbfagonist of the extbfRetinoic Acid Receptor gamma (RAR-gamma) . Activation of this nuclear receptor extbfmodulates gene expression to correct the abnormal growth and shedding of keratinocytes. This molecular cascade extbfprevents follicular hyperkeratinization, resulting in a extbfcomedolytic effect that reduces follicular obstruction.

Conversely, the extbfBenzoyl Peroxide component operates as a extbfnon-specific oxidizing agent, releasing extbffree oxygen radicals that are rapidly toxic to the cell structures of anaerobic extbfC. acnes bacteria. The resulting reduction in the bacterial load, coupled with Adapalene's ability to extbfmodulate inflammatory mediators (like leukotriene B4), yields an extbfantimicrobial and anti-inflammatory effect at the tissue level.

This provides extbfmultitargeting synergy: Adapalene modulates follicular cell differentiation, while Benzoyl Peroxide reduces microbial proliferation. This integrated action influences the development of lesions by reducing follicular hyperkeratinization and suppressing microbial-driven inflammation.

Dosage and Administration Information

How to Use Epiduo Forte

The usage of Epiduo Forte Gel involves specific parameters outlining the route, frequency, and conditions for administration. This medication is designated for topical administration only, applied directly to the skin for cutaneous use.


Application Schedule and Dosing

The gel is typically applied once daily. Application occurs in the evening. A thin layer of the gel is spread over the entire affected area (including the face, chest, or back), and is not restricted only to individual acne lesions.

Before application, the skin should be clean and dry. Use is for the indicated population of adults and pediatric patients 12 years of age and older. If a dose is missed, the next dose is applied at the usual time the following evening, without applying extra product.


Administration Constraints

To ensure proper use, the administration involves specific physical constraints. Contact with sensitive areas, including the eyes, lips, nostrils, and mucous membranes, must be avoided during application. The product is for external use only and is not intended for oral, ophthalmic, or intravaginal administration.

Recent Clinical Evidence

Epiduo Forte: Recent Clinical Evidence

The efficacy of Epiduo Forte (adapalene 0.3%/benzoyl peroxide 2.5%) for the topical treatment of acne vulgaris has been established through randomized, double-blind, vehicle-controlled clinical trials.

Key Efficacy Findings

The primary studies were conducted over 12 weeks, enrolling subjects aged 12 and older with moderate to severe acne. Results indicated a significant difference between the active combination gel and vehicle (placebo) in reducing lesion counts and achieving treatment success.

  • Treatment Success: At the 12-week endpoint, a percentage of participants using Epiduo Forte achieved an Investigator’s Global Assessment (IGA) score of “Clear” or “Almost Clear” with at least a two-grade improvement from baseline. This rate was statistically superior to the vehicle group.
  • Lesion Reduction: The studies reported a greater mean percentage reduction in both inflammatory lesions (papules and pustules) and non-inflammatory lesions (blackheads and whiteheads) in the Epiduo Forte group compared to the vehicle.

Scarring and Long-Term Data

Further research, including the Phase 4 OSCAR trial, has evaluated the potential long-term benefits of early and effective treatment. By significantly decreasing the burden of active acne lesions over a 24-week period, the gel was associated with a reduced risk of developing atrophic (depressed) acne scars in patients with moderate-to-severe acne.

Safety Profile

Local cutaneous irritation reactions are common, particularly during the initial four weeks of treatment. These effects, including erythema (redness), scaling, dryness, and stinging/burning, were generally reported as mild to moderate in intensity and typically lessened with continued use. Severe hypersensitivity reactions are rare but have been reported with benzoyl peroxide products, necessitating immediate discontinuation if symptoms like swelling or difficulty breathing occur.

Key Studies & References

  1. Study Results in Focus: Assessing the Clinical Efficacy of Epiduo® Forte Gel (Summary of Pivotal Trial Endpoints)
  2. New Phase 4 OSCAR Trial Data Showed that Epiduo® Forte (adapalene and benzoyl peroxide) Gel, 0.3%/2.5% Decreased Acne Lesions Therefore Reducing the Risk of Scars in Moderate-to-Severe Acne Patients (Clinical News Release)

Frequently Asked Questions (FAQ)

Common questions about Epiduo Forte (FAQ)


Q: What type of acne is Epiduo Forte gel primarily intended to treat?

A: Epiduo Forte is officially indicated for the treatment of Acne vulgaris when both comedones (blackheads/whiteheads), papules, and pustules are present. According to regulatory information, it is often studied or prescribed for use in patients with moderate to severe acne.


Q: What is the distinction between Epiduo Forte and other combination gels that contain a retinoid and an antimicrobial?

A: This product is a fixed-dose combination of two active ingredients—a retinoid and an antimicrobial. Regulatory documents have noted that the combination is associated with a synergistic action that has demonstrated efficacy in clinical studies for severe acne. This formulation offers a distinct approach by combining two mechanisms in one product to target different factors contributing to acne.


Q: Can the gel potentially cause skin discoloration or changes in the color of the treated area?

A: A change in the color of the treated skin, also known as skin discoloration, has been reported in post-marketing experience. Official safety data indicates that the frequency of this specific reaction cannot be accurately estimated from the information currently available.


Q: How many weeks does it usually take to notice initial changes or improvement in the skin?

A: Studies indicate that early signs of clinical improvement usually appear after 1 to 4 weeks of treatment. Regulatory sources indicate that the full effect of the medication typically takes longer to develop than the initial changes.


Q: What is considered a reasonable timeframe before a user should check with their doctor about lack of improvement?

A: According to official product information, if no improvement is observed after 4–8 weeks of continuous treatment, this is a time point where the benefit of continued treatment is recommended to be reassessed by the prescriber. This timeframe is documented in official guidelines for evaluating treatment response.


Q: Can Epiduo Forte cause bleaching or discoloration of clothing, towels, or hair?

A: Yes, regulatory information states that the product may bleach clothes or hair. Regulatory documents caution that the product should not come into contact with any colored material, including dyed fabrics and hair.


Q: Are there any known interactions with specific oral medications?

A: Official product information suggests that systemic interactions with oral medications are unlikely. This is because the active ingredients are minimally absorbed through the skin. No formal studies have been conducted to assess potential systemic drug-drug interactions.


Q: Are there non-active ingredients in the gel that are known to cause minor irritation, such as propylene glycol?

A: Yes, official product documents note that the gel contains propylene glycol (also known as E1520), which is listed as an excipient that may cause skin irritation.


Q: Is a generic equivalent of Epiduo Forte currently available?

A: Yes, the U.S. Food and Drug Administration (FDA) has approved generic versions of the Adapalene 0.3% and Benzoyl Peroxide 2.5% topical gel, meaning non-branded versions of the product may be available.


Q: Is a temporary increase in dryness and peeling normal when first starting the gel?

A: Yes, local skin reactions like dryness, scaling, and redness are documented as very common. These effects are most likely to occur during the first four weeks of treatment. They are generally reported as mild to moderate and are expected to lessen with continued use.


Q: What is the difference in active ingredient concentration between Epiduo and Epiduo Forte?

A: Epiduo gel contains a concentration of Adapalene 0.1% and Benzoyl Peroxide 2.5%. Epiduo Forte is a higher-strength version that contains Adapalene 0.3% and Benzoyl Peroxide 2.5%.


Q: Can I use exfoliating products like AHA/BHA acids on other parts of my body while using the gel on my face?

A: Regulatory information advises avoiding concomitant use of other potentially irritating topical products and cosmetics with strong drying, abrasive, or peeling properties. This official warning is intended to manage potential cumulative irritation.


Q: Is there an expiry period for the gel once the tube or pump is first opened?

A: Yes, according to official instructions, the tube or pump should be discarded 6 months after first opening; this is the regulated post-opening discard period.


Q: Can Epiduo Forte help improve the appearance of existing acne scars or only active acne?

A: The primary therapeutic indication for the product is the treatment of active acne vulgaris. While clinical research has associated the combination with a reduced risk of developing new scars, the product is not officially indicated for the treatment of existing acne scars.


Q: Is it possible to use Epiduo Forte long-term to manage recurring acne?

A: Regulatory-linked documents note that the lower-strength version of the product has been studied and demonstrated evidence supporting its use as a long-term maintenance therapy. Official documents acknowledge that, as acne is a chronic disease, both acute and long-term therapy are often needed for effective management.


Q: Is the gel typically prescribed as a first-line treatment for acne?

A: Regulatory-linked prescribing resources indicate that the product is often used when acne has not responded to other treatments first. Additionally, a prescriber may first consider the lower-strength version (Epiduo) for individuals with moderate acne.


Q: Is the sensation of burning or stinging expected to decrease or fully resolve with continued use?

A: Official safety information states that local cutaneous reactions, including stinging or burning, are most likely to occur in the first four weeks of treatment. These effects are generally documented to lessen with continued use of the medication.

How should Epiduo Forte be stored and disposed of?

Epiduo Forte gel must be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F), with short excursions permitted. It is essential to keep the gel away from heat and light, and it should not be refrigerated or frozen. The product must always be stored out of the reach of children.

Once the container is first opened, the gel should be discarded after 3 months.

To dispose of the product, do not flush the gel down the toilet or place it into household trash unless local regulations permit. Unused or expired medication and waste materials must be disposed of according to local requirements or by consulting a pharmacist.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Epiduo Forte found in:

A-Z Index: